Clinical trials: Condition
Neurofibromatosis Type 1
PASS of Paediatric Patients Initiating Selumetinib
Neurofibromatosis type 1 (NF1) is a rare, autosomal dominant genetic disorder that is caused by germline mutations in the NF1 tumour suppressor gene, which encodes the tumour suppressor protein neurofibromin 1.
- Trial name
- NCT05388370
- Where
- 46 sites in Austria, France and 8 more
- Volunteers
- 124 people
- Sponsor
- AstraZeneca
Crohn's Disease
Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease
This study will evaluate higher versus standard adalimumab dosing regimens for induction and maintenance therapy in subjects with moderately to severely active Crohn's Disease and evidence of mucosal ulceration.
- Trial name
- NCT02065570
- Testing
- Adalimumab
- Where
- 143 sites in United States, Austria and 18 more
- Volunteers
- 514 people
- Sponsor
- AbbVie
Dry Eye Syndromes
To Evaluate the Efficacy and Safety of HUC3-053 in Patients With Dry Eye Syndrome
This is a multi-center, randomized, double-blinded, non-inferiority study to evaluate the efficacy and safety of HUC3-053 in patients with dry eye syndrome.
- Trial name
- NCT06388070
- Testing
- HA 0.3%, Hyalein Mini Eye Drops
- Where
- South Korea
- Volunteers
- 297 people
- Sponsor
- Huons Co., Ltd.
Migraine Headache
Study in Participants With Acute Migraines Headaches
This is a Phase 2, multicenter, randomized, double-blind, placebo and active comparator-controlled study of LY2590443 in approximately 200 participants with migraines.
- Trial name
- NCT00804973
- Testing
- LY2590443, Sumatriptan
- Where
- 19 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Glioblastoma Multiforme, Adult
A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme
This is an open-label, multicenter, randomized, parallel, 2-arm, efficacy and safety study. Patients with GBM after failure of standard first line therapy will be randomized in a 2:1 ratio to receive berubicin or lomustine for…
- Trial name
- NCT04762069
- Testing
- Berubicin, Lomustine
- Where
- 48 sites in United States, France and 3 more
- Volunteers
- 252 people
- Sponsor
- CNS Pharmaceuticals, Inc.
Venous Leg Ulcer, Pressure Ulcer
Confirm Safety and Performance of Avance Solo and Avance Solo Adapt NPWT Systems
The primary objective of this post market clinical follow-up (PMCF) investigation is to confirm the safety and performance of Avance®Solo and Avance®Solo Adapt NPWT Systems in low to moderate exuding chronic wounds when used in…
- Conditions
- Venous Leg Ulcer, Pressure Ulcer, Diabetic Foot Ulcer, Chronic Ulcer
- Trial name
- ASOLO-CW (NCT04753294)
- Testing
- Avance Solo NPWT System, Avance Solo Adapt NPWT System
- Where
- 13 sites in Belgium, Denmark and 5 more
- Volunteers
- 136 people
- Sponsor
- Molnlycke Health Care AB
Brain Edema, Brain Tumor
XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors
The purpose of this study is to compare the safety and efficacy of XERECEPT® to dexamethasone (Decadron) a common treatment for symptoms of brain swelling (edema).
- Trial name
- NCT00088166
- Testing
- hCRF
- Where
- 34 sites in United States, Canada
- Volunteers
- 200 people
- Sponsor
- Celtic Pharma Development Services
Bladder Cancer
Comparative Study of Hexvix Blue Light Cystoscopy and White Light Cystoscopy in the Detection of Bladder Cancer
A study to compare Hexvix Blue light cstoscopy with standard White light cystoscopy in the detection of bladder cancer.
- Trial name
- NCT05600322
- Testing
- Hexaminolevulinate Hydrochloride, Richard Wolf Photodynamic Diagnostic Equipment (PDD) system
- Where
- 7 sites in China
- Volunteers
- 158 people
- Sponsor
- Photocure
Allergic Rhinitis
Comparative Study of Sinol and Sinol-M in Patients With Congestion Due to Allergic Rhinitis
The purpose of this study is to demonstrate the equivalence of two homeopathic capsaicin containing nasal sprays (Sinol-M™ and Sinol) in patients with nasal congestion due to allergic rhinitis.
- Trial name
- SMAN (NCT00825656)
- Testing
- Sinol or Sinol-M nasal spray
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Strategic Biosciences
Virus Diseases, RNA Virus Infections
Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults
This Phase 3 study is intended to assess the efficacy of the Quadrivalent VLP Influenza Vaccine during the 2017-2018 influenza season in healthy adults 18 to 64 years of age.
- Conditions
- Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
- Trial name
- NCT03301051
- Testing
- Quadrivalent VLP Vaccine
- Where
- 73 sites in United States, Canada and 5 more
- Volunteers
- 10,160 people, healthy volunteers welcome
- Sponsor
- Medicago
Degenerative Disc Disease (DDD), Instabilities
PMCF Study to Evaluate the VERTICALE® Cervical System in Spine Surgery According to Its Intended Use.
In accordance with the European Medical Device Regulation MDR 2017/745/EU, the legal manufacturers of medical devices are obliged to evaluate medical devices with regard to their clinical performance and safety.
- Conditions
- Degenerative Disc Disease (DDD), Instabilities, Trauma, Deformity
- Trial name
- NCT05489822
- Testing
- VERTICALE® Cervical System
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Silony Medical GmbH
Obesity, Overactive Bladder
Trospium Chloride XR in Obese Female Patients With Overactive Bladder
This study evaluated the effectiveness of trospium chloride extended release (XR) in obese female patients with overactive bladder (OAB). Patients received either placebo and trospium chloride XR or placebo only.
- Conditions
- Obesity, Overactive Bladder, Incontinence
- Trial name
- NCT00932022
- Testing
- Trospium Chloride, Extended Release (XR)
- Where
- United States
- Volunteers
- 127 people
- Sponsor
- Allergan
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms (MCS-2-US-c)
This is an open-label extension study of another study protocol, MCS-2-US-a. Subjects who have completed the 12-week treatment and procedures under the protocol MCS-2-US-a will be eligible for this study.
- Trial name
- MCS-2-US-c (NCT01002222)
- Testing
- MCS-2
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Health Ever Bio-Tech Co., Ltd.
Atrial Fibrillation
Tailored vs. Anatomical Ablation Strategy for Persistent Atrial Fibrillation
Atrial Fibrillation (AF) ablation is typically performed in predefined anatomic regions of the left atrium without attempting to identify patient-specific areas of interest.
- Trial name
- Tailored-AF (NCT04702451)
- Testing
- Dispersion ablation + PVI, VX1, PVI
- Where
- 26 sites in United States, Belgium and 3 more
- Volunteers
- 377 people
- Sponsor
- Volta Medical
Asthma, Exercise-Induced
A Study to Investigate the Effects of PT027 (Budesonide/Albuterol Sulfate) Metered-dose Inhaler Compared With Placebo on Exercise-Induced Bronchoconstriction in Adult Patients With Asthma
The purpose of this Phase III, multicentre, randomized, double-blind, single-dose, 2-period, crossover study is to assess the efficacy and safety of PT027 (budesonide/albuterol sulfate) metered-dose inhaler compared with placebo…
- Trial name
- BREATH (NCT06245551)
- Testing
- Budesonide/albuterol metered-dose inhaler 160/180 μg
- Where
- 6 sites in Russia
- Volunteers
- 64 people
- Sponsor
- AstraZeneca
Non-alcoholic Steatohepatitis
Safety, Tolerability, Pharmacokinetics and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis (NASH)
The purpose of this study is to assess the effects of EYP001a (Vonafexor) with respect to safety, tolerability, pharmacokinetics and on markers of liver inflammation in patients with NASH
- Trial name
- NCT03812029
- Testing
- Vonafexor
- Where
- 42 sites in United States, Belgium and 3 more
- Volunteers
- 120 people
- Sponsor
- Enyo Pharma
Refractory Schizophrenia
An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults
This is an adaptive, Phase II/III study in 2 parts (i.e. Part 1 (dose ranging) and Part 2 (Hypothesis testing)). NaBen® is granted Breakthrough Therapy Designation by US FDA as treatment for refractory schizophrenia.
- Trial name
- NCT03094429
- Testing
- NaBen®
- Where
- United States
- Volunteers
- 287 people
- Sponsor
- SyneuRx International (Taiwan) Corp
Cataract Extraction, Corneal Astigmatism
Assessment of Visual Performance in Patients With Low Levels of Astigmatism
To assess visual performance in patients with low levels (0.5-0.75 Diopters) of corneal astigmatism.
- Trial name
- NCT00842231
- Testing
- Visual performance measures
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Alcon Research
Atrial Fibrillation, Atrial Fibrillation, Persistent
RESOLVE-AF: Clinical Evaluation of the Ablacath™ Mapping Catheter and Ablamap® System Utilizing Electrographic Flow (EGF) Mapping to Resolve Extra-PV Sources of Atrial Fibrillation and Guide Ablation Therapy.
Demonstrate the safety and effectiveness of the Ablacath™ Mapping Catheter and Ablamap® System in patients with all types of atrial fibrillation (AF) including paroxysmal or persistent or long-standing persistent, undergoing and…
- Conditions
- Atrial Fibrillation, Atrial Fibrillation, Persistent, Atrial Fibrillation Paroxysmal, Arrhythmia
- Trial name
- RESOLVE-AF (NCT05883631)
- Testing
- Electrographic Flow (EGF) mapping and ablation of EGF-identified sources of Atrial Fibrillation, Electrographic Flow (EGF) mapping (no ablation)
- Where
- 24 sites in United States, Belgium and 2 more
- Volunteers
- 400 people
- Sponsor
- Cortex
Hemophilia B
BeneFIX Drug Use Results Survey [All-Case Surveillance]
The survey is intended to investigate the following matters, etc. under the actual use status after marketing in all patients who are administered this drug for a certain period of time after the launch. 1.
- Trial name
- NCT01154231
- Testing
- Nonacog Alfa (Genetical Recombination)
- Where
- Japan
- Volunteers
- 314 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.